July 25, 2024 11:11 AM EDT
R&D
Pharma

Ab­b­Vie ex­pects $8.7B Cerev­el buy to close ‘as ear­ly as next week,’ new CEO says

Kyle LaHucik

Senior Reporter

Ab­b­Vie said Thurs­day that its high­ly an­tic­i­pat­ed ac­qui­si­tion of Cerev­el Ther­a­peu­tics is slat­ed to close soon. It al­so re­port­ed high­er-than-an­tic­i­pat­ed

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times